The efficacy of lidocaine spray on Pain perception during IUD insertion. A Randomized Controlled Trial.

Thesis submitted as Partial Fulfillment of Master Degree in Obstetrics and Gynecology

By Karim Hussein Zaki Eltawil

M.B.B.Ch – Cairo University – 2008 Resident of Obstetrics and Gynecology Elsahel teaching hospital

Under Supervision of

Prof. Ayman Abd Elrazek Abo Elnoor

Professor of Obstetrics and Gynecology Faculty of medicine Ain Shams University

Dr. Mohamed Elmandooh Mohamed

Assistant professor of Obstetrics and Gynecology Faculty of medicine Ain Shams University

Dr. Ahmed Mohamed Bahaa Eldin Ahmed

Lecturer of Obstetrics and Gynecology Faculty of medicine Ain Shams University

> Faculty of Medicine Ain Shams University 2016

List of Contents

Title	Page	
Review of Literature		
Chapter (1): IUCD	1	
Chapter (2): Anatomy of the Cervix	22	
Chapter (3): Anesthesia of Cervix UTERI	29	
Chapter (4): Lidocaine Hydrochloride	37	
Patients and Methods	42	
Results	49	
Discussion	62	
Conclusion	74	
Recommendations	75	
Summary	76	
References	79	
Arabic summary		

List of Tables

Tab. No.	Title	Page No.
	ce between the 3 gro	
` /	e between the three ground and dysmenorrhea	
	e between the three grouertion	
. ,	e between the three gro	oups regarding anticipated53
• •	between the three group vical grasping and tracti	
	between the three group O insertion	
	between the three group nsertion (5-10 min later	

List of Figures

Fig. N	No. Title	Page No.
Figure (1):	Copper T 380A IUCD	3
Figure (2):	Copper T 380A IUCD inside the Uto	erus 4
Figure (3):	Instruments and Other Key Items Insertion	
Figure (4):	Withdrawing the Insertion Tube Arms	
Figure (5):	Positioning IUCD High in the UIUCD fully inserted in uterus	
Figure (6):	(a) Nulliparous os (b) Parous os	23
Figure (7):	Relation of te cervix	24
Figure (8):	Course of uterine artery	25
Figure (9):	Squamo-columnar junction	26
Figure (10):	Blood supply and lympatic of the ce	rvix 27
Figure (11):	Different ways of local anesthesia cervix	
Figure (12):	Pudenal and paracervical block nee	dle 31
Figure (13):	Block types	31
Figure (14):	Xylocaine Spray	44
Figure (15):	Boxplots for pain expectancy in the	
Figure (16):	Boxplots for pain scores during cer three study groups	
Figure (17):	Boxplots for pain scores during IU three study groups	
Figure (18):	Boxplots for pain scores after IUC three study groups	

LIST OF ABBREVIATIONS

ARHP Association of Reproductive Health Professionals

ARV Antiretroviral

CI Confidence IntervalCOX Cyclo-OxygenaseCS Cesarian SectionDRG Dorsal Root Ganglia

HIV Human Immune Deficiency Virus

HSG Hystrosalpingography

IHP Inferior Hypogastric Plexus

IUCD Intrauterine contraceptive device

LMP Last Menstrual Period

LNG-IUS LevoNorGestrel-releasing IntraUterine System

MEC Medical Eligibility Criteria

NS Not Significant

NSAID Non-Steroidal Anti-Inflammatory Drugs

NVD Normal Vaginal Delivery

OR Odds Ratio

P value probability value

PID Pelvic Inflammatory Disease
 RCT Randomized Controlled Trial
 REA Research Executive Agency
 SHP Superior Hypogastric Plexus

SPSS Statistical Package for the Social Sciences

STI Sexually Transmitted DiseasesUSFDA US Food and Drug Administration

VAS Visual Analogue Scale

WHO World Health Organization



Protocol

Introduction

The intrauterine contraceptive device (IUCD) provides long-term reversible contraception equal in efficacy to tubal sterilization (*Grimes*, 2008). The IUCD is one of the safest, least expensive and most effective contraceptive devices available. The IUCD is often an excellent choice for women who do not anticipate future pregnancies but wish not to be sterilized. It is a convenient method of contraception; once inserted, it is nearly maintenance-free (except for monthly self-checks to locate the IUCD string) for up to a decade. (*Cetinkaya k,et al.*, 2011)

Depending on the country, the use of IUCDs worldwide ranges from 2% to 75%. On average, 15% of reproductive-aged women in developing countries and 8% in developed countries use it (d'Arcangues, 2007).

Increasing the number of women using IUCDs is an important public health goal. Fear of pain during IUCD insertion is one reason women may not want to use this highly effective birth control method. Determining an optimal method for reducing pain during IUCD insertion will benefit women and may increase the uptake of IUCDs as a contraceptive method (Allen et al., 2009).

Components of the insertion procedure that may cause pain include the application of the tenaculum to the cervix to stabilize the uterus and provide traction for straightening the cervical canal, passing the uterine sound, inserting the IUCD in the inserter tube through the cervix, and irritation of the endometrial cavity with the device. (Whiteman et al., 2013)

While some IUCDs are inserted postpartum or postabortal, most are inserted remote (more than four weeks) from pregnancy as a clinic-based procedure. The levels of pain that women experience during IUCD insertion vary in published reports. Most women experience mild to moderate discomfort during IUCD insertion. Rarely, the pain is severe and associated

with nausea and weakness and sometimes, pain may persist for a few days after insertion. Predictors of pain during IUCD insertion include age greater than 30 years, lengthier time since last pregnancy or last menses, and not currently breastfeeding (*Hubacher*, 2006). Psychosocial factors including expected pain also influence the pain perceived by women undergoing the procedure (*Goldstuck*, 1985; *Murty*, 2003).

Pain perception from the cervix and the corpus of the uterus appears to pass through two distinct neural pathways. Innervation to the cervix arises from parasympathetic fibers from the pelvic splanchnic nerves (S2–4), which also supply the lower portion of the uterus and travel up to hypogastric nerves to the lower thoracic spinal cord (Moore et al., 1999).

Different ways of reducing pain during IUCD insertion have been explored. These include drugs that reduce cramping of the uterus (NSAIDs), drugs that soften and open the cervix, and drugs that numb the cervix. Prophylactic NSAIDs, as studied, do not appear to reduce pain during IUCD insertion (Massey, 1974; Jensen, 1998; Hubacher, 2006). The use of misoprostol to prime the cervix in addition to diclofenac before IUCD insertion did not appear to reduce pain and may increase side effects (Ibrahim et al., 2013).

Currently, we have no good evidence to recommend a specific method to reduce pain during IUCD insertion (Allen et al., 2009).

The oral mucosal use of lidocaine 10% spray has been seen as a safe and effective way of pain control in dentistry (*Karasahin et al., 2009*), which inspired us for this study.

Topical agents may be applied either to the exocervix or in the cervical canal while vehicles include spray solutions and topical gels and creams. The use of topical anesthetic sprays on the exocervix has generally

been demonstrated ineffective for biopsy, (*Prefontaine et al., 1991*) but one well designed, placebo-controlled RCT demonstrated that there was less pain with tenaculum attachment. (*Soriano D et al. 2000*).

Local anesthetics that are administered topically may decrease cervical pain by blocking pain nerve fibers. (Gemzell-Danielsson K et al., 2013).

Evaluation of pain as a symptom is difficult because it is subjective feeling and composed of sensory, emotional and cognitive components. Pain tolerance is deeply influenced by culture. A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. This validated pain scale uses a 10 cm line to represent the continuum of 'no pain' to 'worst imaginable pain' (Sriwatanakul et al., 1983).